The efficacy and safety of probiotics intervention in preventing conversion of impaired glucose tolerance to diabetes: study protocol for a randomized, double-blinded, placebo controlled trial of the Probiotics Prevention Diabetes Programme (PPDP)

BMC Endocrine Disorders

Bo Feng¹  Xu Li¹  Qun Yan¹ 

[1] Department of Endocrinology, Shanghai East Hospital, Tongji University School of Medicine, Jimo Road 150, Shanghai, China

关键词: Impaired glucose tolerance;    Diabetes;    Probiotics;   

Others  :  1234626
DOI  :  10.1186/s12902-015-0071-9

 received in 2015-10-26, accepted in 2015-11-17,  发布年份 2015

【 摘 要 】

Background

Alterations in intestinal microbiota correlate with risk of development of obesity and type 2 diabetes. Probiotics have been suggested to play an important role in the management of dysglycemia, although the evidence is limited. In this study, we aim to explore the efficacy and safety of probiotics intervention in preventing type 2 diabetes in Chinese patients with impaired glucose tolerance.

Methods/Design

A 24-month randomized intervention is conducted from January 2014 to December 2016. The target sample size for intervention is 200 middle-aged men and women aged 30–65 year-old with impaired glucose tolerance. Participants with persistent impaired glucose tolerance were assigned to group A (tablet A) and B (tablet B) in sequential order. The participants and investigators were blinded to the assignment. The primary outcome is development of diabetes. The secondary outcome measures include body composition, biochemical variables and the safety of the probiotics.

Discussion

The results from this trial will provide the evidence on the efficacy and safety of probiotics administration in preventing conversion of impaired glucose tolerance to diabetes in a Chinese context.

Trial registration

ChiCTRTRC13004024

【 授权许可】

   
2015 Yan et al.

【 图 表 】

Fig. 1.

【 参考文献 】

• [1]Xu Y, Wang L, He J, Bi Y, Li M, Wang T et al.. Prevalence and control of diabetes in Chinese adults. JAMA. 2013; 310:948-59.
• [2]Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001; 344:1343-50.
• [3]Pan XR, Li GW, Hu YH, Wang JX, Yang WY, An ZX et al.. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance: the Da Qing IGT and Diabetes Study. Diabetes Care. 1997; 20:537-44.
• [4]Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA et al.. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002; 346:393-403.
• [5]Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P et al.. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomized controlled trial. Lancet. 2006; 368:1096-105.
• [6]Gong QH, Kang JF, Ying YY, Li H, Zhang XH, Wu YH et al.. Lifestyle interventions for adults with impaired glucose tolerance: a systematic review and meta-analysis of the effects on glycemic control. Intern Med. 2015; 54:303-10.
• [7]Knowler WC, Hamman RF, Edelstein SL, Barrett-Connor E, Ehrmann DA, Walker EA et al.. Prevention of type 2 diabetes with troglitazone in the diabetes prevention program. Diabetes. 2005; 54:1150-6.
• [8]Zinman B, Harris SB, Neuman J, Gerstein HC, Retnakaran RR, Raboud J et al.. Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): a double-blind randomised controlled study. Lancet. 2010; 376:103-11.
• [9]Hu R, Li Y, Lv Q, Wu T, Tong N. Acarbose monotherapy and type 2 diabetes prevention in Eastern and Western Prediabetes: an ethnicity-specific meta-analysis. Clin Ther. 2015; 37:1798-812.
• [10]Bäckhed F, Ding H, Wang T, Hooper LV, Koh GY, Nagy A et al.. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci U S A. 2004; 101:15718-23.
• [11]Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature. 2006; 444:1027-31.
• [12]Karlsson FH, Tremaroli V, Nookaew I, Bergstrom G, Behre CJ, Fagerberg B et al.. Gut metagenome in European women with normal, impaired and diabetic glucose control. Nature. 2013; 498:99-103.
• [13]Qin J, Li Y, Cai Z, Li S, Zhu J, Zhang F et al.. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature. 2012; 490:55-60.
• [14]Cani PD, Neyrinck AM, Fava F, Knauf C, Burcelin RG, Tuohy KM et al.. Selective increases of bifidobacteria in gut microflra improves high-fat diet-induced diabetes through a mechanism associated with endotoxemia. Diabetologia. 2007; 50:2374-83.
• [15]Wagnerberger S, Spruss A, Kanuri G, Stahl C, Schröder M, Vetter W et al.. Lactobacillus casei Shi-rota protects from fructose-induced liver steatosis: a mouse model. J Nutr Biochem. 2013; 24:531-8.
• [16]Ejtahed HS, Mohtadi-Nia J, Homayouni-Rad A, Niafar M, Asghari-Jafarabadi M, Mofid V. Probiotic yogurt improves antioxidant status in type 2 diabetic patients. Nutrition. 2012; 28:539-43.
• [17]Shakeri H, Hadaegh H, Abedi F, Tajabadi-Ebrahimi M, Mazroii N, Ghandi Y et al.. Consumption of synbiotic bread decreases triacylglycerol and VLDL levels while increasing HDL levels in serum from patients with type-2 diabetes. Lipids. 2014; 49:695-701.
• [18]Lindsay KL, Brennan L, Kennelly MA, Maguire OC, Smith T, Curran S et al.. Impact of probiotics in women with gestational diabetes mellitus on metabolic health: a randomized controlled trial. Am J Obstet Gynecol. 2015; 212:496.e1-11.
• [19]Mahboobi S, Iraj B, Maghsoudi Z, Feizi A, Ghiasvand R, Askari G et al.. The effects of probiotic supplementation on markers of blood lipids, and blood pressure in patients with prediabetes: a randomized clinical trial. Int J Prev Med. 2014; 5:1239-46.
• [20]Qian Q, Li X, Huang X, Fu M, Meng Z, Chen M et al.. Glucose metabolism among residents in Shanghai: natural outcome of a 5-year follow-up study. J Endocrinol Invest. 2012; 35:453-8.
• [21]Lian F, Li G, Chen X, Wang X, Piao C, Wang J et al.. Chinese herbal medicine Tianqi reduces progression from impaired glucose tolerance to diabetes: a double-blind, randomized, placebo-controlled, multicenter trial. J Clin Endocrinol Metab. 2014; 99:648-55.
• [22]Everard A, Matamoros S, Geurts L, Delzenne NM, Cani PD. Saccharomyces boulardii administration changes gut microbiota and reduces hepatic steatosis, low-grade inflammation, and fat mass in obese and type 2 diabetic db/db mice. MBio. 2014; 5:e01011-4.